Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 19.25p 18.50p 20.00p 19.25p 19.25p 19.25p 2,071 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.8 -10.0 0.0 - 146.32

Tissue Regenix (TRX) Latest News

More Tissue Regenix News
Tissue Regenix Takeover Rumours

Tissue Regenix (TRX) Share Charts

1 Year Tissue Regenix Chart

1 Year Tissue Regenix Chart

1 Month Tissue Regenix Chart

1 Month Tissue Regenix Chart

Intraday Tissue Regenix Chart

Intraday Tissue Regenix Chart

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix Forums and Chat

Date Time Title Posts
23/9/201607:25Tissue Regenix delivering practical solutions to real clinical issues1,807
24/5/201610:30Third time lucky6,918
29/6/201321:26TOREX 2007 - THE TILLS RING AT LAST8
24/3/201312:45Torex - an insiders tale23
24/9/201210:10Torex Retailing8

Add a New Thread

Tissue Regenix (TRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:54:0718.602,071385.21O
View all Tissue Regenix trades in real-time

Tissue Regenix (TRX) Top Chat Posts

DateSubject
26/9/2016
09:20
Tissue Regenix Daily Update: Tissue Regenix is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 19.25p.
Tissue Regenix has a 4 week average price of 19.55p and a 12 week average price of 19.40p.
The 1 year high share price is 22.50p while the 1 year low share price is currently 13.25p.
There are currently 760,124,264 shares in issue and the average daily traded volume is 59,690 shares. The market capitalisation of Tissue Regenix is £146,323,920.82.
02/8/2016
09:00
channel pirate: Igbert, It looks as though TRX may have called this wrong then this time with the Edison Report. O.K. I agree it reads well, but it looks to have caused a temporary negative reaction to the share price. I did add a few more yesterday at 18.35p and am quite happy to hold. Looks like Mr Woodford was still buying in the 19's !!
27/7/2016
07:08
multibagger: Hi Swiss Paul, Some very valid and searching questions. The biotech/healthcare product market is a very complex one due to various procurement and payment schemes/methods. In the UK, the NHS is a slow adopter and constrained by cost.The US is a much higher cost healthcare system and if TRX finds traction there, then there will be an uplift in share price. Though I keep an eye on TRX, I am not of the view that the share price will move upwards fast and not invested currently. I'm not a fan of either Odell or Samuels having met them both in Leeds at the AGM a few years ago, when I was the only shareholder present ! I'm not convinced about their their tech pipeline either, as regenerative medicine is moving a lot quicker than TRX are. I sold out not long after. My approach to biotech investing has changed and now largely go for funds....I hold AXA Framlington Biotech though I made good money from SCLP, SUMM and SAR in the past.Cyprotex (CRX) is moving in the right direction and their R&D product delivery and commercialisation is much more attractive - I pointed it out here when it was about 60p on this board - now about 135p. I hope TRX comes good for all holders - but my take is that investors may have a fairly long wait. Good luck all :)
30/6/2016
14:56
andrewbaker: Woodford has said he's still holding TRX and sold some for cash raising purposes, the directors have foregone an instant reward for a deferred one in the future, and only then if the share price performs, so they are supportive; and the company sells much outside of the UK, so is an exporter who will benefit from the fall in the UK currency. So, how come the price falls!? Maybe there's shorter term profit taking happening; but, as I'm a long term investor, that doesn't concern me so much: this business is a long term success story, in my view. Buying in now, or adding to an existing holding, has to be a profitable strategy for future profits, IMHO.
30/6/2016
08:13
bamboo2: Could be interim results from Meniscus trial as soon as next week. =========================================== 30 June 2016 Tissue Regenix Group plc Deferred Annual Bonus Scheme Leeds, 30 June 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Company") the regenerative medical devices company announces that an award has been made to Ian Jefferson, Chief Financial Officer and Antony Odell, Chief Executive Officer, pursuant to the terms of the Company's Deferred Annual Bonus Scheme. Under the terms of the Deferred Annual Bonus Scheme, Ian Jefferson waived his entitlement to receive 50% of his annual cash bonus in return for an option over 209,677 ordinary shares of 0.5p each in the Company and Antony Odell waived his entitlement to receive 36% of his annual cash bonus in return for an option over 255,484 ordinary shares of 0.5p each in the Company (the "Deferred Allocation"). The number of shares comprising the Deferred Allocation (i.e. subject to option) was calculated by dividing the amount of cash bonus waived by the closing market value of the ordinary shares of the Company on the dealing day immediately prior to the date of deferral. The Deferred Allocation option is not capable of exercise until the vesting date has been reached, which is three years from the date of the award. By participating in the Deferred Annual Bonus Scheme Ian Jefferson and Antony Odell are entitled to receive a matching award at no additional cost (the "Matching Allocation"), being an option over 629,031 and 766,452 ordinary 0.5p shares in the Company respectively. The Matching Allocation is not capable of exercise until the vesting date has been reached, which is three years from the date of award. Additionally, the Matching Allocation is not capable of exercise until the Company's share price has reached the following target prices and remained at those prices for at least 30 consecutive days: Performance criteria % Of Interest .Share Price To Vest ..........Criteria -------------- ------------ 33.33% .........20p -------------- ------------ 33.33%......... 25p -------------- ------------ 33.33%......... 30p -------------- ------------
31/5/2016
14:13
luminoso: Mmm, the quieter the board, the better the share price, it seems ! If it breaks 22p, can't see much holding us back til 30p. Edit - Doh ! Spoke too soon !
25/1/2016
08:34
igbertsponk: Hmm... paid for report signalling additional cash needed this year. Can't see the share price rising for a while with that hanging over it.
01/6/2015
09:26
igbertsponk: yes, brought a warm glow to the share price !
12/5/2015
07:45
bamboo2: 12 May 2015 Tissue Regenix Group Plc ("Tissue Regenix" or "the Company") Deferred Annual Bonus Award The Company today announces that an award has been made to Ian Jefferson, Chief Financial Officer and Antony Odell, Chief Executive Officer, pursuant to the terms of the Company's Deferred Annual Bonus Plan. Under the terms of the Deferred Annual Bonus Plan, Ian Jefferson waived his entitlement to receive 50% of his annual cash bonus in return for an option over 126,494 ordinary shares of 0.5p each in the Company and Antony Odell waived his entitlement to receive 28% of his annual cash bonus in return for an option over 129,870 ordinary shares of 0.5p each in the Company (the "Deferred Allocation"). The number of shares comprising the Deferred Allocation (i.e. subject to option) was calculated by dividing the amount of cash bonus waived by the closing market value of the ordinary shares of the Company on the dealing day immediately prior to the date of deferral. The Deferred Allocation option is not capable of exercise until the vesting date has been reached, which is three years from the date of the award. By participating in the Deferred Annual Bonus Plan Ian Jefferson and Antony Odell are entitled to receive a matching award at no additional cost (the "Matching Allocation"), being an option over 379,482 and 389,610 ordinary 0.5p shares in the Company respectively. The Matching Allocation is not capable of exercise until the vesting date has been reached, which is three years from the date of award. Additionally, the Matching Allocation is not capable of exercise until the Company's share price has reached the following target prices and remained at those prices for at least 30 consecutive days: Performance criteria % Of Interest Share Price To Vest Criteria -------------- ------------ 33.33% 25p -------------- ------------ 33.33% 30p -------------- ------------ 33.33% 35p -------------- ------------
22/4/2015
22:01
bamboo2: The AIM 100 Http://www.investorschronicle.co.uk/2015/04/17/shares/the-aim-WCbiP2R34VNfrk9vHANY2N/article.html 99. TISSUE REGENIX You could say Tissue Regenix (TRX)is a classic Aim-traded, blue-sky story. The medical devices outfit successfully launched its DermaPure product - aimed at treating chronic wounds - in the US last year. Accordingly, its share price soared 150 per cent in the nine months to May 2014. That left the company well on the way to targeting the skin-substitutes market, estimated to be worth roughly $1.4bn (£867m). But the share price has halved since then, and the group went through with an equity placing at the start of 2015 to raise another £20m. It’s thought the proceeds will go towards the development and launch of Tissue Regenix’s human meniscus and human ligament products, the expansion of the direct salesforce for DermaPure and the continued development and commercialisation of the company’s porcine-derived products. Analysts at Jefferies expect TRX’s meniscus products - for knee cartilage injuries - to launch in the US and Europe by 2017, with sales of $5.6m in the first year and $19.4m in the second year. Roughly 1.5m people a year in Europe and the US are affected by knee injuries. But, until then, the company will have to rely on sales of DermaPure and even further equity fundraisings to fund its clinical programme. Buy. HR
02/1/2014
12:50
multibagger: Hi BB2...my discussion and points of view are largely academic....market seems to be supportive of an upward trending TRX share price and I am certainly not complaining :) The market is what matters and decides the share price, not my opinion !
Tissue Regenix share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20160926 10:32:11